Greenleaf Trust Takes $217,000 Position in UiPath Inc. (NYSE:PATH)

Greenleaf Trust purchased a new stake in shares of UiPath Inc. (NYSE:PATH) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 8,735 shares of the healthcare company’s stock, valued at approximately $217,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of UiPath by 7.6% in the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after buying an additional 2,673,718 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of UiPath by 3,273.3% in the third quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock worth $26,777,000 after buying an additional 1,518,592 shares during the last quarter. FMR LLC boosted its holdings in shares of UiPath by 2.9% in the third quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after buying an additional 463,032 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of UiPath by 179.9% in the third quarter. Los Angeles Capital Management LLC now owns 715,688 shares of the healthcare company’s stock worth $12,245,000 after buying an additional 459,965 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of UiPath by 857.7% in the fourth quarter. Federated Hermes Inc. now owns 458,126 shares of the healthcare company’s stock worth $11,380,000 after buying an additional 410,288 shares during the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Trading Up 0.7 %

UiPath stock opened at $19.69 on Thursday. The firm’s 50 day moving average price is $22.42 and its 200-day moving average price is $21.55. UiPath Inc. has a 1 year low of $12.38 and a 1 year high of $27.87.

UiPath (NYSE:PATH) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The company had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. On average, equities analysts forecast that UiPath Inc. will post -0.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PATH shares. Mizuho raised their price objective on shares of UiPath from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Thursday, March 14th. Morgan Stanley lifted their price target on shares of UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a report on Thursday, March 14th. KeyCorp began coverage on shares of UiPath in a report on Monday, April 8th. They set an “overweight” rating and a $27.00 price target on the stock. William Blair began coverage on shares of UiPath in a report on Tuesday, January 2nd. They set an “outperform” rating on the stock. Finally, Barclays lifted their price target on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, March 15th. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.41.

Insider Buying and Selling

In related news, CFO Ashim Gupta sold 16,000 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now owns 87,505 shares in the company, valued at $1,998,614.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 72,000 shares of company stock worth $1,591,360. Insiders own 31.03% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.